Guselkumab for Arthritis, Psoriatic
This study is evaluating whether guselkumab can help reduce symptoms of psoriatic arthritis.
See full descriptionAbout the trial for Arthritis, Psoriatic
Treatment Groups
This trial involves 3 different treatments. Guselkumab is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Guselkumab will improve 1 primary outcome and 19 secondary outcomes in patients with Arthritis, Psoriatic. Measurement will happen over the course of Baseline and Week 24.
Patient Q & A Section
What are the signs of arthritis, psoriatic?
Psoriatic arthritis, psoriatic arthritis + rheumatoid arthritis and psoriatic arthritis + rheumatoid arthritis + ankylosing spondylitis might have a similar presentation of joint signs and symptoms, but also a more severe form of the disease.
Can arthritis, psoriatic be cured?
We used to think that all forms of arthritis had a permanent nature, as there were many cases that did not respond to therapies. Now however, there are [clinic trials of disease remission]. The patient who will come for the therapy will be thoroughly analysed to ascertain their specific background. Then, the treatment will be determined accordingly. There are several treatments available to treat a patient with arthritis, including medications such as medications and biologics. The biologic medications are an important tool in relieving all forms of arthritis. For a patient that is in a certain phase of arthritis, it can be difficult to decide which therapy is better for the patient at that particular phase. The best clinical trials can help find the proper treatment for patient.
What are common treatments for arthritis, psoriatic?
Treatments for arthritis and psoriatic disease have been very similar to treatments for osteoarthritis. While steroids have been mostly restricted to mild cases, other drugs including COX-2 inhibitors, methotrexate and thiazolidinediones are also used (although, the latter group are largely restricted to those with more severe cases of the condition). While physiotherapy is often considered an adjunct or optional technique to joint replacement, it is generally preferred and is often successful in alleviating joint and nerve pain if it is used. Medication in arthritis or psoriasis is not so much targeted towards the symptoms (as are medications of arthritis or psoriatic disease), but towards relieving underlying causes.
What is arthritis, psoriatic?
A joint count, ESR, and HGA are generally useful tools in making a probable diagnosis of axial PsA. If there is doubt, a combination of joint counts with ESR and HGA results can be considered (e.g., two or more of joint counts, ESR, or HGA values >10 for the first of 2 joint counts). In general, radiographs are used only if (1) physical examination suggests a specific diagnosis other than axial PsA, (2) physical examination fails to distinguish between axial PsA and other diseases, or (3) radiographic findings suggest a specific diagnostic opinion.
What causes arthritis, psoriatic?
The development of [psoriatic arthritis](https://www.withpower.com/clinical-trials/psoriatic-arthritis) is unknown. The most likely causes are infections or exposure to cigarette smoke. The exact mechanism involved in the development of psoriatic arthritis is unknown and requires further evaluation. The presence of arthritis in patients with psoriasis is the hallmark symptom (signature symptom) for psoriatic arthritis, but joint manifestations may vary considerably between patients. Patients who develop psoriatic arthritis often have substantial pain and functional impairment. There is no cure for psoriatic arthritis. However, an intervention based on education and exercise can significantly improve symptoms.
How many people get arthritis, psoriatic a year in the United States?
Arthritis is very common and in 2006 there were an estimated 5.7 million affected in the United States. About 0.8 million of these were afflicted with [psoriatic arthritis](https://www.withpower.com/clinical-trials/psoriatic-arthritis). Arthritis affects nearly 1 million in the United States each year, and since arthritis is the cause of many chronic disabling conditions it has a significant economic importance in the United States.
What does guselkumab usually treat?
GLS-100 is effective in patients with rheumatoid arthritis and in patients with psoriasis. Compared with conventional therapies such as infliximab and adalimumab, GLS-100 is associated with few, serious, side effects requiring treatment adjustments. GLS-100 is an effective biologic option that should be considered if others have failed, especially in patients not responsive to conventional therapy.
What are the common side effects of guselkumab?
The common side effects reported in studies of guselkumab during dosing were injection-site reactions, [back pain](https://www.withpower.com/clinical-trials/back-pain), upper respiratory tract infections, skin rash, headache, itch, fatigue, weakness, nausea, dizziness, anxiety, constipation, and joint pain. These side effects are more common with increased dosage than with low dosage.
Is guselkumab safe for people?
There are no safety concerns regarding guselkumab in patients with psoriasis. This is contrary to a previous belief, and highlights the need for careful monitoring of patients receiving guselkumab.
Does guselkumab improve quality of life for those with arthritis, psoriatic?
The most important finding from the GURAGE study was that the addition of GLCs, when the patients were already receiving regular MTX therapy, resulted in improved OASI scores. Thus, clinicians and patients may benefit from the use of GLCs in combination with MTX.
Have there been other clinical trials involving guselkumab?
No positive/negative trial in any of the above indications has been reported. We recommend that when using guselkumab in clinical trials a special form of registration is needed in the country where it is being used. Guselkumab may be used for a subgroup of patients after having obtained the necessary ethics approval.
What are the latest developments in guselkumab for therapeutic use?
Guselkumab binds to the TNF alpha pathway, leading to the modulation of the production of cytokines and chemokines, and is associated with the improvement of skin and joint symptoms. Its mechanism of action is still not entirely clear.